AIM
MRSN

Alambic Investment Management’s Mersana Therapeutics MRSN Stock Holding History

Alambic Investment Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-562
Closed -$221K – 410
2018
Q1 		$221K Buy
+562
New +$222K 0.03% 406

Other funds holding MRSN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Alambic Investment Management's MRSN Position: Q2 2018 in Review

Alambic Investment Management sold out of Mersana Therapeutics (MRSN) in Q2 2018, closing a stake of 562 shares — an estimated $221K sold.

Alambic Investment Management first reported a position in MRSN in Q1 2018 and held it in 1 quarter. The position peaked at $221K in Q1 2018. 53 funds tracked by Wall St. Rank hold MRSN as of Q2 2018.

  • Alambic Investment Management reported no remaining Mersana Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 562 Mersana Therapeutics shares in Q2 2018, an estimated $221K.
  • Alambic Investment Management first reported a position in Mersana Therapeutics in Q1 2018 and held it in 1 quarter.
  • Alambic Investment Management's Mersana Therapeutics position peaked at $221K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.